You are here: Industry Insights > Opdivo

News List

NICE rejects Opdivo for preventing melanoma recurrence pharmatimes
November 27, 2018
NHS funding for use of Bristol-Myers Squibb’s Opdivo as an adjuvant treatment for resected stage III and IV melanoma is being blocked by the National Institute for Health and Care Excellence.
Amazing Monthly Sales Performance of Opdivo and Keytruda in China Xiaoyaowan
November 06, 2018
It was revealed that by September 30, i.e., about one month after the marketing in China, the sales revenue of the two anti-PD-1 monoclonal antibody drugs: Opdivo and Keytruda separately reached RMB 190 million and RMB 150 million, showing amazing perform
KOL Views: How does Opdivo’s stumble shift the balance of power in SCLC? biospectrumasia
October 17, 2018
KOL Views Imfinzi Keytruda Opdivo Tecentriq AstraZeneca BMS Merck & Co. Roche EMA FDA Lung Cancer Pulmonary/Respiratory Medicine Marketing & Sales Medical Affairs
Merck follows Opdivo’s suit, prices Keytruda in China at half its U.S. tag fiercepharma
September 20, 2018
When Bristol-Myers Squibb unveiled its price for Opdivo in China, industry watchers considered it a benchmark against which future immuno-oncology therapies will look to for their pricing strategies.
Merck extends I/O lead as EU Oks Keytruda in first line lung cancer biopharmadive
September 17, 2018
Keytruda (pembrolizumab) continues to dominate in first-line NSCLC approvals, which have fueled its rapid sales growth and transformed Merck into an immunotherapy leader.
The day has come: Merck’s Keytruda surpasses Bristol-Myers Squibb’s Opdivo in Q2 sales fiercepharma
July 30, 2018
Merck & Co.’s blockbuster cancer drug Keytruda has delivered again in the second quarter, and this time, it has seized the PD-1/L1 crown from Bristol-Myers Squibb’s archrival Opdivo.
Bristol-Myers surprise: Threatened I-O drug Opdivo stands its ground in lung cancer fiercepharma
July 30, 2018
Investors may be worried about Bristol-Myers Squibb’s future in lung cancer, but in the meantime, the company’s portfolio is firing on all cylinders.
Bristol-Myers Squibb commercial chief Gordon jumps ship ahead of key Opdivo launch fiercepharma
July 24, 2018
Bristol-Myers Squibb is locked in some pretty big marketing battles—but it’ll have to soldier on without its commercial leader.
Final NICE no for BMS’ Opdivo in urothelial carcinoma pharmatimes
July 05, 2018
The National Institute for Health and Care Excellence has now issued final guidance rejecting NHS funding for use of Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).
BMS' Opdivo becomes first immuno-oncology agent available in China pharmafile
June 22, 2018
Bristol-Myers Squibb’s flagship immunotherapy Opdivo (nivolumab) has broken ground to become the first and only PD-1 inhibitor to be made available in China.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page